Comparison of in vivo and in vitro evolution of CCR5 to CXCR4 coreceptor use of primary human immunodeficiency virus type 1 variants

Virology

Volumn 412, Issue 2, 2011, Pages 269-277

  Edo Matas, Diana ^a   van Dort, Karel A ^a   Setiawan, Laurentia C ^a   Schuitemaker, Hanneke ^a   Kootstra, Neeltje A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

CCR5; Coreceptor switch; Coreceptor use; CXCR4; Envelope; HIV 1; R5; V3; X4

Indexed keywords

ARGININE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLUTAMIC ACID; GLYCINE; GLYCOPROTEIN GP 120; PROLINE; SERINE; VIRUS ENVELOPE PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CELL GROWTH; COCULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; VIRUS CULTURE; VIRUS ISOLATION; VIRUS REPLICATION;

CELL LINE; GENE PRODUCTS, ENV; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION, MISSENSE; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, HIV; SEQUENCE ANALYSIS, DNA; VIRUS ATTACHMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79952619253     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.01.010     Document Type: Article

References (88)

1. Alkhatib G., et al. CC CKR5: a RANTES, MIP-1β, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958.
2. Ashorn P.A., Berger E.A., Moss B. Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells. J. Virol. 1990, 64:2149-2156.
3. Berson J.A., et al. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J. Virol. 1996, 70:6288-6295.
4. Bjorndal A., et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 1997, 71:7478-7487.
5. Bleul C.C., et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382:829-832.
6. Boyd M.T., Simpson G.R., Cann A.J., Johnson M.A., Weiss R.A. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J. Virol. 1993, 67:3649-3652.
7. Brumme Z.L., et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J. Infect. Dis. 2005, 192:466-474.
8. Bunnik E.M., Quakkelaar E.D., van Nuenen A.C., Boeser-Nunnink B., Schuitemaker H. Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient. J. Virol. 2007, 81:525-531.
9. Carrillo A., Ratner L. Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells. J. Virol. 1996, 70:1310-1316.
10. Carrillo A., Ratner L. Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J. Virol. 1996, 70:1301-1309.
11. Chesebro B., Wehrly K., Nishio J., Perryman S. Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J. Virol. 1996, 70:9055-9059.
12. Choe H., et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85:1135-1148.
13. Clapham P.R., Blanc D., Weiss R.A. Specific cell surface requirements for the infection of CD4 positive cells by human immunodeficiency virus types 1 and 2 and by simian immunodeficiency virus. Virology 1994, 181:703-705.
14. Cocchi F., et al. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat. Med. 1996, 2:1244-1247.
15. Connor R.I., Sheridan K.E., Ceradini D., Choe S., Landau N.R. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 1997, 185:621-628.
16. Cordonnier A., Montagnier L., Emerman M. Single amino-acid changes in HIV envelope affect viral tropism and receptor binding. Nature 1989, 340:571-574.
17. Dalgleish A.G., et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312:763-767.
18. De Jong J.J., De Ronde A., Keulen W., Tersmette M., Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J. Virol. 1992, 66:6777-6780.
19. De Roda Husman A.M., et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann. Intern. Med. 1997, 127:882-890.
20. De Roda Husman A.M., van Rij R.P., Blaak H., Broersen S., Schuitemaker H. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for HIV-1 disease progression. J. Infect. Dis. 1999, 180:1106-1115.
21. Deen K.C., et al. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 1988, 331:82-84.
22. Dejucq N., Simmons G., Clapham P.R. T-cell line adaptation of human immunodeficiency virus type 1 strain SF162: effects on envelope, vpu and macrophage-tropism. J. Gen. Virol. 2000, 81:2899-2904.
23. Deng H.K., et al. Identification of the major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
24. Deng H.K., Unutmaz D., KewalRamani V.N., Littman D.R. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 1997, 388:296-300.
25. Doranz B.J., et al. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3 and CKR-2b as fusion cofactors. Cell 1996, 85:1149-1158.
26. Dragic T., et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
27. Edinger A.L., et al. Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins. Virology 1998, 249:367-378.
28. Edo-Matas D., et al. Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection. Virology 2010, 405:492-504.
29. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
30. Fouchier R.A., et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J. Virol. 1992, 66:3183-3187.
31. Fouchier R.A.M., Brouwer M., Broersen S.M., Schuitemaker H. Simple determination of human immunodeficiency virus type 1 syncytium inducing genotype by PCR. J. Clin. Microbiol. 1995, 33:906-911.
32. Gulick R.M., et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J. Infect. Dis. 2007, 196:304-312.
33. Gulick R.M., et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 2008, 359:1429-1441.
34. Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp. Ser. 1999, 41:95-98.
35. Harrowe G., Cheng-Mayer C. Amino acid changes in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1. Virology 1995, 210:490-494.
36. Hoffman N.G., Seillier-Moiseiwitsch F., Ahn J., Walker J.M., Swanstrom R. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J. Virol. 2002, 76:3852-3864.
37. Hu Q., et al. Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J. Virol. 2000, 74:11858-11872.
38. Hu Q., et al. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization. J. Mol. Biol. 2000, 302:359-375.
39. Huang W., et al. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J. Virol. 2008, 82:5584-5593.
40. Hwang S.S., Boyle T.J., Lyerly H.K., Cullen B.R. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991, 253:71-74.
41. Jansson M., et al. Length variation of glycoprotein 120 V2 region in relation to biological phenotypes and coreceptor usage of primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 2001, 17:1405-1414.
42. Jensen M.A., et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J. Virol. 2003, 77:13376-13388.
43. Jensen M.A., Coetzer M., Van 't Wout A.B., Morris L., Mullins J.I. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J. Virol. 2006, 80:4698-4704.
44. Karlsson A., Parsmyr K., Sandstrom E., Fenyö E.M., Albert J. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J. Clin. Microbiol. 1994, 32:364-370.
45. Kim F.M., Kolson D.L., Balliet J.W., Srinivasan A., Collman R.G. V3-independent determinants of macrophage tropism in a primary human immunodeficiency virus type 1 isolate. J. Virol. 1995, 69:1755-1761.
46. Kiselyeva Y., et al. Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations. J. Virol. 2007, 81:3657-3661.
47. Klatzmann D., et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984, 312:767-768.
48. Koot M., et al. HIV-1 biological phenotype in long term infected individuals, evaluated with an MT-2 cocultivation assay. AIDS 1992, 6:49-54.
49. + cell depletion and progression to AIDS. Ann. Intern. Med. 1993, 118:681-688.
50. Koot M., et al. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J. Infect. Dis. 1996, 173:349-354.
51. Koot M., et al. Conversion rate towards a syncytium inducing (SI) phenotype during different stages of HIV-1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J. Infect. Dis. 1999, 179:254-258.
52. Kootstra N.A., Schuitemaker H. Phenotype of HIV-1 lacking a functional nuclear localization signal in matrix protein of GAG and Vpr is comparable to wild type HIV-1 in primary macrophages. Virology 1999, 253:170-180.
53. Kozak S.L., et al. CD4, CXCR-4, and CCR5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J. Virol. 1997, 71:873-882.
54. Labrosse B., Treboute C., Brelot A., Alizon M. Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor. J. Virol. 2001, 75:5457-5464.
55. Maddon P.J., et al. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986, 47:333-348.
56. Mariani R., et al. Mouse-human heterokaryons support efficient human immunodeficiency virus type 1 assembly. J. Virol. 2001, 75:3141-3151.
57. Marozsan A.J., et al. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005, 338:182-199.
58. Mild M., Esbjornsson J., Fenyo E.M., Medstrand P. Frequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switch. J. Virol. 2007, 81:3369-3376.
59. Moncunill G., Armand-Ugon M., Pauls E., Clotet B., Este J.A. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro. AIDS 2008, 22:23-31.
60. Mosier D.E., et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 1999, 73:3544-3550.
61. Moyle G.J., et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J. Infect. Dis. 2005, 191:866-872.
62. Nabatov A.A., et al. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J. Virol. 2004, 78:524-530.
63. Pastore C., Ramos A., Mosier D.E. Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J. Virol. 2004, 78:7565-7574.
64. Pastore C., et al. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J. Virol. 2006, 80:750-758.
65. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophage tropic isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72:2855-2864.
66. Posada D., Crandall K.A. Modeltest: testing the model of DNA substitution. Bioinformatics 1998, 14:817-818.
67. Richman D.D., Bozzette S.A. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J. Infect. Dis. 1994, 169:968-974.
68. Rucker J., et al. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J. Virol. 1997, 71:8999-9007.
69. Safrit J.T., Lee A.Y., Andrews C.A., Koup R.A. A region in the third variable loop of HIV-1 gp120 is recognized by HLA-B7 restricted CTLs from two acute seroconversion patients. J. Immunol. 1994, 153:3822-3830.
70. Scarlatti G., et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine mediated suppression. Nat. Med. 1997, 3:1259-1265.
71. Schuitemaker H., et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J. Virol. 1992, 66:1354-1360.
72. Schuitemaker H., et al. Envelope V2 configuration and HIV-1 phenotype: clarification. Science 1995, 268:115.
73. Shimizu N., et al. Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein. Virology 1999, 259:324-333.
74. Shimizu N., et al. A putative G protein-coupled receptor, RDC1, is a novel coreceptor for human and simian immunodeficiency viruses. J. Virol. 2000, 74:619-626.
75. Shimizu N., et al. Broad usage spectrum of G protein-coupled receptors as coreceptors by primary isolates of HIV. AIDS 2009, 23:761-769.
76. Shioda T., Levy J.A., Cheng-Mayer C. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 1991, 349:167-169.
77. Shioda T., Levy J.A., Cheng-Mayer C. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA 1992, 89:9434-9438.
78. Sing T., et al. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir. Ther. 2007, 12:1097-1106.
79. Smyth R.J., Yi Y., Singh A., Collman R.G. Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency virus type 1 primary isolate. J. Virol. 1998, 72:4478-4484.
80. Tersmette M., et al. Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV-p24 gag. Virology 1989, 171:149-155.
81. Trkola A., et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384:184-187.
82. van Rij R.P., et al. Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. J. Clin. Invest. 2000, 106:1039-1052.
83. van Rij R.P., Worobey M., Visser J.A., Schuitemaker H. Evolution of R5 and X4 human immunodeficiency virus type 1 gag sequences in vivo: evidence for recombination. Virology 2003, 314:451-459.
84. Van 't Wout A.B., Schuitemaker H., Kootstra N.A. Isolation and propagation of HIV-1 on peripheral blood mononuclear cells. Nat. Protoc. 2008, 3:363-370.
85. Wu L., et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996, 384:179-183.
86. Zhang L., et al. Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72:9307-9312.
87. Zhang Y.-J., et al. Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J. Virol. 1998, 72:9337-9344.
88. Zhang M., et al. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 2004, 14:1229-1246.